Siltuximab for Multicentric Castleman Disease—Letter
نویسندگان
چکیده
منابع مشابه
Siltuximab for Multicentric Castleman Disease-Letter.
We read with great interest the article by Deisseroth and colleagues (1) focusing on the recent global approval of the monoclonal IL6 antibody siltuximab for the treatment of patients with HHV-8-, HIV-negative multicentric Castleman disease (MCD). Up to now, treatment options for this rare lymphoproliferative disorder are very limited. Lately, the phase III, double-blind, randomized trial of va...
متن کاملFDA approval: siltuximab for the treatment of patients with multicentric Castleman disease.
On April 22, 2014, the FDA granted full approval to siltuximab (SYLVANT for injection; Janssen Biotech, Inc.), a chimeric human-mouse monoclonal antibody to IL6, for the treatment of patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. The approval was primarily based on the results of a randomized, doub...
متن کاملEmerging treatments in Castleman disease - a critical appraisal of siltuximab.
Castleman disease (CD) is a rare, heterogeneous lymphoproliferative disorder for which no standard of care currently exists. Evidence that the pathophysiology of CD is fueled by excessive interleukin-6 (IL-6) has led to considerable interest in therapeutic targeting of this cytokine. Siltuximab, a chimeric monoclonal antibody to IL-6, has thus emerged as a promising treatment option in a diseas...
متن کاملChronic Myelomonocytic Leukemia following Multicentric Castleman Disease
Multicentric Castleman disease (MCD) is a rare nonmalignant lymphoproliferative disorder presenting systemic symptoms such as fever, night sweats, fatigue, anemia, effusions, and multifocal lymphadenopathy. The etiology of MCD has not been clarified to date. The coexistence of MCD with chronic myelomonocytic leukemia (CMML) has been rarely reported. Although the pathogenesis remains unclear, th...
متن کاملMulticentric Castleman disease: consensus at last?
In collaboration with an international cohort of clinicians and pathologists who reviewed more than 240 cases, the authors concurred on a set of evidence-based criteria, thereby paving the way for a uniform approach to managing this enigmatic condition. In 1956, Castleman et al described clinicopathologic features of 13 asymptomatic patients who presented with a mediastinal mass. This form of u...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2015
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-15-1310